Benzenesulfonamides
Matrix Scientific 4-CYANOBENZENESULFONAMIDE-1G
4-Cyanobenzenesulfonamide, 97%; 1g,C7H6N2O2S, MFCD00178767, mw 182.20, [3119-02-6]
Apexbio Technology LLC Sildenafil mesylate 1308285-21-3 25mg
Sildenafil mesylate (CAS 1308285-21-3) is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) exhibiting an IC50 of 3 5 nM By inhibiting PDE5-mediated cGMP hydrolysis it enhances endogenous cGMP levels particularly within corpus cavernosum tissue In vitro sildenafil mesylate reversibly potentiates relaxation responses in precontracted corpus cavernosum strips following sodium nitroprusside exposure or electrical stimulation and increases intracellular cGMP in treated smooth muscle cells In vivo it augments erectile responses in anesthetized canine models This compound is widely used for studying PDE5-related signaling pathways and pharmacological modulation in erectile and vascular function research
eMolecules 1005264-47-0 | Medchem Express | MX69 | 5mg | 446256267 | HY-100892 | MFCD24858136 | 474.58 | C27H26N2O4S
Medchem Express | 14-Chrysenequinone | 50mg | 437899125 | HY-111441 | 100900-16-1 | MFCD00009941 | 258.276 | C18H10O2
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Medchemexpress LLC Bosentan (hydrate) | 157212-55-0 | 99.9% | C27H31N5O7S | 1 ML
Bosentan hydrate is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors, with Ki values of 4.7 nM and 95 nM respectively, in human smooth muscle cells. This product is for research use only.
- Competitive and dual antagonist of endothelin-1 (ET)
- Targets ETA and ETB receptors
- Ki values of 4.7 nM for ETA receptor and 95 nM for ETB receptor
- For research use only
- Appearance: Off-white to light yellow solid
- Melting point: 114-118°C
Medchemexpress LLC HY-100573 5mg Medchemexpress, (E)-Necrosulfonamide CAS:1360614-48-7 Purity:>98%
Medchemexpress, HY-100573 5mg (E)-Necrosulfonamide CAS:1360614-48-7 (E)-Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL) to block the necrosome formation. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Medchemexpress LLC HY-112292 5mg Medchemexpress, GW806742X CAS:579515-63-2 Purity:>98%
Medchemexpress, HY-112292 5mg GW806742X CAS:579515-63-2 GW806742X is a Mixed Lineage Kinase Domain-Like protein (MLKL) inhibitor which binds the MLKL pseudokinase domain with a K d value of 9.3 μM and has anti-necroptosis activity. GW806742X has activity against VEGFR2 [1] [2] . Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Medchemexpress LLC Seclidemstat mesylate | 2044953-70-8 | 99.8% | 547.04 g/mol | C20H23ClN4O4S·CH4O3S | 100 MG
Seclidemstat mesylate is the mesylate salt of seclidemstat (SP-2577), a reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (KDM1A/LSD1) used in preclinical research. It exhibits potent biochemical activity and is investigated for antitumor immunity and cancer research applications, including studies of Ewing sarcoma and SWI/SNF-mutated ovarian cancer.
- Reversible, noncompetitive KDM1A (LSD1) inhibitor.
- Demonstrates potent biochemical activity (Ki ≈ 31 nM; IC50 ≈ 13 nM).
- High purity suitable for research (99.8%).
- Provided as a mesylate salt to improve handling and stability.
- Supplied as a powder; store at 4°C away from moisture and light.
- Used in oncology and virology research applications.
Medchemexpress LLC Glimepiride | 93479-97-1 | 99.9% | C24H34N4O5S | 5 G
Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic compound. It has shown to lower blood glucose more effectively than glibenclamide and may decrease extracellular Aβ40 and Aβ42 levels, suggesting its potential for Alzheimer's disease associated with diabetes.
- Medium-to-long acting sulfonylurea anti-diabetic compound.
- Lower risk of hypoglycemia and less weight gain compared to other sulfonylureas.
- May be safer for patients with cardiovascular disease due to a lack of detrimental effects on ischemic preconditioning.
- Potential for Alzheimer's disease associated with diabetes by decreasing extracellular Aβ40 and Aβ42 levels.
Medchemexpress LLC Glimepiride | 93479-97-1 | 99.9% | C24H34N4O5S | 500 MG
Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound. It acts mainly by stimulating insulin release from pancreatic beta cells and increasing the sensitivity to insulin at receptor sites, thereby lowering blood sugar. Glimepiride is effective in controlling blood glucose and is often used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Medium-to-long acting anti-diabetic compound
- Stimulates insulin release from pancreatic beta cells
- Increases insulin sensitivity at receptor sites
- Effective in controlling blood glucose
- Used to improve glycemic control in type 2 diabetes mellitus
Sigma Aldrich Fine Chemicals Biosciences Bosentan Related Compound C United States Pharmacopeia (USP) Reference Standard | 1097263-60-9 | 15MG
Bosentan Related Compound C United States Pharmacopeia (USP) Reference Standard | Mol Wt: 1041.16 | 1097263-60-9 | 15MG
Apexbio Technology LLC Glimepiride 93479-97-1 5g
Glimepiride (CAS 93479-97-1) is a sulfonylurea compound widely used in research on type 2 diabetes It primarily acts by enhancing glucose uptake both in the presence and absence of insulin In cultured cells glimepiride (10 M) increases 2-deoxyglucose uptake to 186% of control and upregulates GLUT1 and GLUT4 expression to 164% and 148% of control respectively indicating insulin-independent mechanisms for stimulating cardiac glucose uptake In rodent models glimepiride administration reduced diabetes incidence by 23% in BB rats and decreased blood glucose HbA1c and plasma insulin levels in KK-Ay mice highlighting its utility for investigating glucose metabolism and diabetes pathophysiology
eMolecules 133745-75-2 | N-Fluorobenzenesulfonimide | Ambeed | MFCD00144885 | 315.330 | C12H10FNO4S2 | 98.000 | FN(S(=O)(=O)c1ccccc1)S(=O)(=O)c1ccccc1 | 5g | 552734398
N-Fluorobenzenesulfonimide | Ambeed | 133745-75-2 | MFCD00144885 | 315.330 | C12H10FNO4S2 | 98.000 | FN(S(=O)(=O)c1ccccc1)S(=O)(=O)c1ccccc1 | 5g | 552734398